News >

Expert Sees Biosimilars as Integral to Expanding Access, Controlling Costs in Oncology

Caroline Seymour
Published: Monday, Jul 16, 2018

Yelena Novik, MD

Yelena Novik, MD

The field of oncology may not be sustainable from a cost perspective without greater use of cost-saving agents, like biosimilars, and the development of more cost-efficient approaches to new drug development, said Yelena Novik, MD, an associate professor at NYU Langone’s Perlmutter Cancer Center.

Regulatory advances regarding biosimilars have been coming into the oncology field. In December 2017, the FDA approved the trastuzumab biosimilar MYL-1401O (Ogivri; trastuzumab-dkst) for use in patients with HER2-positive breast cancer in addition to HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Several other trastuzumab (Herceptin) biosimilars are under investigation.

More recently, results from the phase III HERITAGE trial presented at the 2018 ASCO Annual Meeting showed that the addition of MYL-1401O to a taxane as first-line therapy followed by MYL-1401O maintenance mirrored the progression-free survival rate at 48 weeks compared with trastuzumab in patients with HER2-positive metastatic breast cancer.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication